Idexx Laboratories IDXX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 246.3%+4.0pp | 242.3%+2.9pp | 239.4%+3.4pp | 235.9%+0.7pp | |
| Operating margin | 123.2%+6.7pp | 116.4%-0.5pp | 117%+9.9pp | 107%-7.5pp | |
| Net margin | 96.4%+5.5pp | 90.9%+2.0pp | 88.9%+6.2pp | 82.7%-12.1pp | |
| Returns | |||||
| Return on equity | 255%+2.8pp | 252.2%-118pp | 370%-63.1pp | 433.1%-115pp | |
| Return on invested capital | 202%+16.6pp | 185.5%-27.6pp | 213.1%+8.0pp | 205.1%-27.7pp | |
| Efficiency | |||||
| Asset turnover | 4.9×+0.1× | 4.8×-0.2× | 5×-0.3× | 5.3×-0.2× | |
| Liquidity | |||||
| Current ratio | 4.7×-1.0× | 5.7×+0.3× | 5.4×+1.6× | 3.8×-2.2× | |
| Leverage | |||||
| Debt-to-equity | 1.7×-0.2× | 2×-1.1× | 3.1×-3.5× | 6.6×+1.2× | |
| Net debt / EBITDA | 1.4×0.0× | 1.4×-0.8× | 2.2×-0.9× | 3×-0.1× | |
| Per Share | |||||
| Book value per share | $74.85-1.9% | $76.28+35.8% | $56.17+118% | $25.72-23.0% | |
| Valuation | |||||
| Market capitalization | $181.83B+13.0% | $160.95B-2.9% | $165.74B+21.5% | $136.46B-33.0% | |
| Price / earnings | 182.1×-3.9× | 186×-24.9× | 210.9×+13.5× | 197.4×-82.4× | |
| Price / sales | 44×+1.8× | 42.3×-4.4× | 46.7×+5.6× | 41.1×-25.1× | |
| Price / book | 119.1×+17.9× | 101.2×-45.4× | 146.6×-102× | 249×-32.5× | |
| EV / EBITDA | 129.8×-2.2× | 132.1×-14.3× | 146.4×+7.3× | 139.1×-71.5× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Idexx Laboratories's profit margins?
- Idexx Laboratories (IDXX) runs a 62.1% gross margin and a 31.6% operating margin, with a 24.6% net margin.
- Where do Idexx Laboratories's ratios come from?
- Every ratio is computed from Idexx Laboratories's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
